Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A 25-gene panel predicting the benefits of immunotherapy in head and neck squamous cell carcinoma.

International immunopharmacology - 1 Sept 2022

Huang Yongsheng, Liao Jianwei, Liang Faya, Lin Peiliang, Wu Sangqing, Ye Yuchu, Gao Ming, Chen Renhui, Zeng Haicang, Yin Xinke, Jiang Yuanling, Ouyang Nengtai, Han Ping, Huang Xiaoming

Abstract excerpt

Tumor mutation burden high (TMB-H) is widely used in the guidance of immune checkpoint blocking (ICB) therapy for head and neck squamous cell carcinoma (HNSCC) patients. However, a few patients still had a poor response. Therefore, it is necessary to investigate a better model to guide ICB therapy. We constructed a genomic mutation model conducive to ICB therapy using an available HNSCC dataset. Moreover,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Cancer Immunotherapy and Biomarkers

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Ferroptosis and cancer prognosis

Share to Head and Neck Neoplasms

Share to Immunotherapy

Share to Lung Cancer Treatments and Mutations

Share to Mutation

Share to Squamous Cell Carcinoma of Head and Neck

Source

Identifiers

PMID: 35816946
DOI: 10.1016/j.intimp.2022.108846

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A 25-gene panel predicting the benefits of immunotherapy in head and neck squamous cell carcinoma.PMID 35816946Read ↗

Tumor mutational burden predictability in head and neck squamous cell carcinoma patients treated with immunotherapy: systematic review and meta-analysis.Semantic proximity Read ↗

Multimodal genomic markers predict immunotherapy response in the head and neck squamous cell carcinomaSemantic proximity Read ↗

Identification of factors related to immunotherapy efficacy and prognosis in patients with advanced head and neck squamous cell carcinoma.Semantic proximity Read ↗

A mutational signature and significantly mutated driver genes associated with immune checkpoint inhibitor response across multiple cancers.Semantic proximity Read ↗

Comparative Analysis of Mutation Status and Immune Landscape for Squamous Cell Carcinomas at Different Anatomical sites.Semantic proximity Read ↗

Tumor Mutation Burden, Immune Cell Infiltration, and Construction of Immune-Related Genes Prognostic Model in Head and Neck Cancer.Semantic proximity Read ↗

A mutation-based gene set predicts survival benefit after immunotherapy across multiple cancers and reveals the immune response landscape.Semantic proximity Read ↗

Identification of Immune-related lncRNA Panel for Predicting Immune Checkpoint Blockade and Prognosis in Head and Neck Squamous Cell CarcinomaSemantic proximity Read ↗

A 20-gene mutation signature predicts the efficacy of immune checkpoint inhibitor therapy in advanced non-small cell lung cancer patients.Semantic proximity Read ↗

Immune related gene signature derived from integrate machine learning algorithm predicts outcomes of HNSC patientsSemantic proximity Read ↗

Clinical-genomic determinants of immune checkpoint blockade response in head and neck squamous cell carcinoma.Semantic proximity Read ↗

Continuous Prediction for Tumor Mutation Burden Based on Transcriptional Data in Gastrointestinal CancersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.